ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 100 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.65 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,129,165 | -33.9% | 1,040,754 | 0.0% | 0.75% | -56.5% |
| Q2 2023 | $10,792,619 | +28.2% | 1,040,754 | 0.0% | 1.73% | +5.0% |
| Q1 2023 | $8,419,700 | -88.3% | 1,040,754 | -77.2% | 1.64% | -86.4% |
| Q4 2022 | $71,882,402 | +0.1% | 4,563,962 | 0.0% | 12.11% | +9.2% |
| Q3 2022 | $71,837,000 | +12.8% | 4,563,962 | 0.0% | 11.08% | -11.7% |
| Q2 2022 | $63,713,000 | -19.0% | 4,563,962 | 0.0% | 12.55% | -1.6% |
| Q1 2022 | $78,683,000 | +18.6% | 4,563,962 | 0.0% | 12.75% | +40.5% |
| Q4 2021 | $66,360,000 | -19.2% | 4,563,962 | 0.0% | 9.07% | -14.0% |
| Q3 2021 | $82,151,000 | +2.5% | 4,563,962 | 0.0% | 10.55% | +8.5% |
| Q2 2021 | $80,143,000 | -14.5% | 4,563,962 | +22.7% | 9.72% | -4.4% |
| Q1 2021 | $93,759,000 | +641.3% | 3,720,582 | +90.3% | 10.17% | +446.9% |
| Q4 2020 | $12,648,000 | – | 1,954,932 | – | 1.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |